196.80 % to Target, H.C. Wainwright Keeps ‘”Buy”’ Rating on Inovio Pharmaceuticals (NASDAQ:INO) Shares Today

December 7, 2017 - By Michael Collier

 196.80 % to Target, H.C. Wainwright Keeps ‘

Inovio Pharmaceuticals (NASDAQ:INO) Rating Reaffirmed

New York: In a note sent to investors on 6 October, H.C. Wainwright reaffirmed their “Buy” rating on Inovio Pharmaceuticals (NASDAQ:INO) shares. They now have a $13.0 target on the firm. H.C. Wainwright’s target would suggest a potential upside of 196.80 % from the company’s last close price.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $11.0 target in Thursday, October 5 report. The stock has “Buy” rating by H.C. Wainwright on Wednesday, August 9. On Thursday, November 9 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Monday, March 14 by Brean Capital. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, October 25 report. The rating was downgraded by Zacks to “Hold” on Friday, August 14. The stock of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) earned “Buy” rating by H.C. Wainwright on Tuesday, October 17. Aegis Capital maintained the shares of INO in report on Thursday, June 1 with “Buy” rating. PiperJaffray upgraded the shares of INO in report on Thursday, June 8 to “Overweight” rating. Maxim Group maintained the shares of INO in report on Thursday, June 8 with “Buy” rating.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Globenewswire.com which released: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” on November 27, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” on December 06, 2017. Fool.com‘s news article titled: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” with publication date: November 09, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.